Cargando…
Does Statin Therapy Reduce the Risks of Mortality and Major Adverse Cardiac and Cerebrovascular Events in Young Adults with End-Stage Renal Disease? Population-Based Cohort Study
Among hemodialysis patients aged more than 40 years old, previous large-scale studies showed statin treatment had no effect on reducing cardiovascular adverse events. However, young-adult-onset end-stage renal disease (ESRD) patients have different physicosocial factors compared to older ESRD patien...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8152985/ https://www.ncbi.nlm.nih.gov/pubmed/34068144 http://dx.doi.org/10.3390/jcm10102097 |
_version_ | 1783698703226241024 |
---|---|
author | Cheng, Ya-Lien Yang, Huang-Yu Wu, Chao-Yi Tsai, Chung-Ying Chen, Chao-Yu Hsiao, Ching-Chung Hsu, Hsiang-Hao Tian, Ya-Chung Yen, Chieh-Li |
author_facet | Cheng, Ya-Lien Yang, Huang-Yu Wu, Chao-Yi Tsai, Chung-Ying Chen, Chao-Yu Hsiao, Ching-Chung Hsu, Hsiang-Hao Tian, Ya-Chung Yen, Chieh-Li |
author_sort | Cheng, Ya-Lien |
collection | PubMed |
description | Among hemodialysis patients aged more than 40 years old, previous large-scale studies showed statin treatment had no effect on reducing cardiovascular adverse events. However, young-adult-onset end-stage renal disease (ESRD) patients have different physicosocial factors compared to older ESRD patients. The benefit of statins in such a specific group has not been well evaluated. Through the use of Taiwan’s National Health Insurance Research Database (NHIRD), young adult patients aged 20–40 with incident ESRD requiring permanent dialysis between 1 January 2003 and 31 December 2015 were identified. The enrollees were further divided into two groups depending on whether they received statin therapy for more than 90 days (statin group) or never received any statin (nonstatin group) in the first year after initiation of dialysis. Propensity score weighting (PSW) was used to balance the baseline characteristics between the two groups. After PSW, the statin group (n = 771) exhibited a higher rate of major adverse cardiac and cerebrovascular events (MACCEs) (2.65% vs. 1.44%, hazard ratio (HR): 1.87, 95% confidence interval (CI): 1.43–2.45), and acute myocardial infarction (1.51% vs. 0.30%, HR: 5.34, 95% CI: 3.40–8.39) compared to the nonstatin group (n = 1709). The risk of all-cause mortality, cardiovascular (CV) death. and stroke did not significantly differ between the two groups. Similar to older patients, this study demonstrated that statin therapy cannot offer any protective effects in reducing CV outcomes among young adult ESRD patients undergoing dialysis. |
format | Online Article Text |
id | pubmed-8152985 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-81529852021-05-27 Does Statin Therapy Reduce the Risks of Mortality and Major Adverse Cardiac and Cerebrovascular Events in Young Adults with End-Stage Renal Disease? Population-Based Cohort Study Cheng, Ya-Lien Yang, Huang-Yu Wu, Chao-Yi Tsai, Chung-Ying Chen, Chao-Yu Hsiao, Ching-Chung Hsu, Hsiang-Hao Tian, Ya-Chung Yen, Chieh-Li J Clin Med Article Among hemodialysis patients aged more than 40 years old, previous large-scale studies showed statin treatment had no effect on reducing cardiovascular adverse events. However, young-adult-onset end-stage renal disease (ESRD) patients have different physicosocial factors compared to older ESRD patients. The benefit of statins in such a specific group has not been well evaluated. Through the use of Taiwan’s National Health Insurance Research Database (NHIRD), young adult patients aged 20–40 with incident ESRD requiring permanent dialysis between 1 January 2003 and 31 December 2015 were identified. The enrollees were further divided into two groups depending on whether they received statin therapy for more than 90 days (statin group) or never received any statin (nonstatin group) in the first year after initiation of dialysis. Propensity score weighting (PSW) was used to balance the baseline characteristics between the two groups. After PSW, the statin group (n = 771) exhibited a higher rate of major adverse cardiac and cerebrovascular events (MACCEs) (2.65% vs. 1.44%, hazard ratio (HR): 1.87, 95% confidence interval (CI): 1.43–2.45), and acute myocardial infarction (1.51% vs. 0.30%, HR: 5.34, 95% CI: 3.40–8.39) compared to the nonstatin group (n = 1709). The risk of all-cause mortality, cardiovascular (CV) death. and stroke did not significantly differ between the two groups. Similar to older patients, this study demonstrated that statin therapy cannot offer any protective effects in reducing CV outcomes among young adult ESRD patients undergoing dialysis. MDPI 2021-05-13 /pmc/articles/PMC8152985/ /pubmed/34068144 http://dx.doi.org/10.3390/jcm10102097 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Cheng, Ya-Lien Yang, Huang-Yu Wu, Chao-Yi Tsai, Chung-Ying Chen, Chao-Yu Hsiao, Ching-Chung Hsu, Hsiang-Hao Tian, Ya-Chung Yen, Chieh-Li Does Statin Therapy Reduce the Risks of Mortality and Major Adverse Cardiac and Cerebrovascular Events in Young Adults with End-Stage Renal Disease? Population-Based Cohort Study |
title | Does Statin Therapy Reduce the Risks of Mortality and Major Adverse Cardiac and Cerebrovascular Events in Young Adults with End-Stage Renal Disease? Population-Based Cohort Study |
title_full | Does Statin Therapy Reduce the Risks of Mortality and Major Adverse Cardiac and Cerebrovascular Events in Young Adults with End-Stage Renal Disease? Population-Based Cohort Study |
title_fullStr | Does Statin Therapy Reduce the Risks of Mortality and Major Adverse Cardiac and Cerebrovascular Events in Young Adults with End-Stage Renal Disease? Population-Based Cohort Study |
title_full_unstemmed | Does Statin Therapy Reduce the Risks of Mortality and Major Adverse Cardiac and Cerebrovascular Events in Young Adults with End-Stage Renal Disease? Population-Based Cohort Study |
title_short | Does Statin Therapy Reduce the Risks of Mortality and Major Adverse Cardiac and Cerebrovascular Events in Young Adults with End-Stage Renal Disease? Population-Based Cohort Study |
title_sort | does statin therapy reduce the risks of mortality and major adverse cardiac and cerebrovascular events in young adults with end-stage renal disease? population-based cohort study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8152985/ https://www.ncbi.nlm.nih.gov/pubmed/34068144 http://dx.doi.org/10.3390/jcm10102097 |
work_keys_str_mv | AT chengyalien doesstatintherapyreducetherisksofmortalityandmajoradversecardiacandcerebrovasculareventsinyoungadultswithendstagerenaldiseasepopulationbasedcohortstudy AT yanghuangyu doesstatintherapyreducetherisksofmortalityandmajoradversecardiacandcerebrovasculareventsinyoungadultswithendstagerenaldiseasepopulationbasedcohortstudy AT wuchaoyi doesstatintherapyreducetherisksofmortalityandmajoradversecardiacandcerebrovasculareventsinyoungadultswithendstagerenaldiseasepopulationbasedcohortstudy AT tsaichungying doesstatintherapyreducetherisksofmortalityandmajoradversecardiacandcerebrovasculareventsinyoungadultswithendstagerenaldiseasepopulationbasedcohortstudy AT chenchaoyu doesstatintherapyreducetherisksofmortalityandmajoradversecardiacandcerebrovasculareventsinyoungadultswithendstagerenaldiseasepopulationbasedcohortstudy AT hsiaochingchung doesstatintherapyreducetherisksofmortalityandmajoradversecardiacandcerebrovasculareventsinyoungadultswithendstagerenaldiseasepopulationbasedcohortstudy AT hsuhsianghao doesstatintherapyreducetherisksofmortalityandmajoradversecardiacandcerebrovasculareventsinyoungadultswithendstagerenaldiseasepopulationbasedcohortstudy AT tianyachung doesstatintherapyreducetherisksofmortalityandmajoradversecardiacandcerebrovasculareventsinyoungadultswithendstagerenaldiseasepopulationbasedcohortstudy AT yenchiehli doesstatintherapyreducetherisksofmortalityandmajoradversecardiacandcerebrovasculareventsinyoungadultswithendstagerenaldiseasepopulationbasedcohortstudy |